



Attorneys Docket No. 9368-6IP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Olmstead et al.
Serial No.: 09/991,258
Filed: November 16, 2001
For: *Alphavirus Vectors and Virosomes with Modified HIV Genes for Use in Vaccines*

Confirmation No.: 4473
Group Art Unit: 1642

Date: April 16, 2003

Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a form PTO-1449, together with a copy of the identified document(s). This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,

Mary L. Miller
Registration No. 39,303



20792

PATENT TRADEMARK OFFICE

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on April 16, 2003.

Monica L. Croom

1642
#9
IDS
PATENT
w/attack
6.26.03
RECEIVED
TECH CENTER 1600/2900
APR 23 2003